Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04202341 · ClinicalTrials.gov registry record
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
A clinical trial of Generalized Myasthenia Gravis, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT04202341 is a study of Generalized Myasthenia Gravis that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 500 participants, above the 112-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (346% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT04202341, a study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Conditions Studied
Study Locations (20)
California
- Clinical Trial Site - Fresno
- Clinical Trial Site - Orange
- Clinical Trial Site - Rancho Mirage
- Clinical Trial Site - Sylmar
Florida
- Clinical Trial Site - Clearwater
- Clincal Trial Site - Gainesville
- Clinical Trial Site - Jacksonville
- Clinical Trial Site - Tampa
Colorado
- Clinical Trial Site - Colorado Springs
- Clinical Trial Site - Fort Collins
Alabama
- Clinical Trial Site - Birmingham
Arizona
- Clinical Trial Site - Scottsdale
Connecticut
- Clinical Trial Site - New Haven
District of Columbia
- Clinical Trial Site - Washington D.C.
Georgia
- Clinical Trial Site - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2029-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04202341
The ClinicalTrials.gov registry entry for NCT04202341 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 112-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (346% higher). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 0 interventions.
NCT04202341 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT04202341 about?
NCT04202341 is a clinical study titled "Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)". Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
What is the current status of trial NCT04202341?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2019-12-02. Estimated completion is 2029-10-01.
What conditions does trial NCT04202341 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
Who is sponsoring clinical trial NCT04202341?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04202341 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
RECRUITING
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.